

# 2019 Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

<https://marketpublishers.com/r/2783F82AB29EN.html>

Date: April 2019

Pages: 57

Price: US\$ 1,799.00 (Single User License)

ID: 2783F82AB29EN

## Abstracts

The global clinical trial report- “2019 Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Non-Proliferative Diabetic Retinopathy (NPDR). It presents in-depth analysis of Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Non-Proliferative Diabetic Retinopathy (NPDR).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials by-

Current Trial Status

Type of the trial

Sponsor Type

Enrollment Trends

Region

Countries

Trial Phase

The report also identifies the potential drug candidates under development for treatment of Non-Proliferative Diabetic Retinopathy (NPDR)

The research work is prepared through extensive and continuous research on Non-Proliferative Diabetic Retinopathy (NPDR) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

#### Report Scope and Coverage:

All major trials from 2010 to 2019 and planned trials are included in the report scope.

Drug candidates currently being researched for administering Non-Proliferative Diabetic Retinopathy (NPDR) patients are identified

The report includes panorama of Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials across the globe

Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided

Companies and universities focusing on Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)

Average Enrollment number, insights into enrollment trends, company wise enrollment are included

Both interventional and observational studies are analyzed

News and latest developments for the past one year are presented in the report

## Contents

### 1. TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

### 2. EXECUTIVE SUMMARY

2.1 Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials Overview, 2019

2.2 Premium Insights into Clinical Trials

2.2.1 Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Region

2.2.2 Average Enrollment of Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials

2.2.3 Companies participating in Trials

2.2.4 Drugs under Study for Non-Proliferative Diabetic Retinopathy (NPDR) Treatment, 2019

### 3. REGION WISE NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) CLINICAL TRIALS

3.1 Asia Pacific Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country

3.2 Europe Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country

3.3 North America Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country

3.4 Middle East and Africa Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country

3.5 South and Central America Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country

### 4. NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) CLINICAL TRIAL TRENDS

4.1 Start Year wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials

4.2 Phase wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials

4.3 Trial Status wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials

4.4 Trial Type wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials

## **5. NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) AVERAGE ENROLLMENT TRENDS**

5.1 Average Enrollment in Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Year

5.2 Average Enrollment in Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Phase

5.3 Average Enrollment in Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Status

5.4 Average Enrollment in Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Type of Trial

## **6. COMPANIES PARTICIPATING IN NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) CLINICAL TRIALS**

6.1 Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Sponsor Type

6.2 Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Sponsor Type

6.3 Subjects Recruited by Leading Sponsors

## **7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS**

7.1 Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase

7.2 Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase

7.3 Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase

7.4 Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase

## **8. APPENDIX**

8.1 Report Guidance

8.2 Research Methodology

8.3 Abbreviations

8.4 Definitions

8.5 Sources

8.6 Publisher Expertise

## List Of Figures

### LIST OF FIGURES

Figure 1: Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Region, 2019

Figure 2: Country wise Clinical Trials, 2019

Figure 3: Country wise Average Enrolment, 2019

Figure 4: Asia Pacific – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment

Figure 5: Europe – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment

Figure 6: Middle East Africa – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment

Figure 7: North America – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment

Figure 8: South and Central America – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment

Figure 9: Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Phase

Figure 10: Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Trial Status

Figure 11: Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Type

Figure 12: Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Sponsor Type

Figure 13: Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Leading Sponsors

Figure 14: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Phase

Figure 15: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Trial Status

Figure 16: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Type

Figure 17: Non-Proliferative Diabetic Retinopathy (NPDR)- Average Enrolment by Type of Sponsors

Figure 18: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Leading Sponsors

Figure 19: VPAResearch- Research Methodology

## List Of Tables

### LIST OF TABLES

- Table 1: Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials Snapshot- 2019
- Table 2: Trials by Region, 2019
- Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
- Table 4: Asia Pacific – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
- Table 5: Europe – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
- Table 6: Middle East Africa – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
- Table 7: North America – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
- Table 8: South and Central America – Country wise Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
- Table 9: Clinical Trials by Phase
- Table 10: Clinical Trials by Trial Status
- Table 11: Clinical Trials by Type
- Table 12: Clinical Trials by Sponsor Type
- Table 13: Clinical Trials by Leading Sponsors
- Table 14: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Phase
- Table 15: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Trial Status
- Table 16: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Type
- Table 17: Non-Proliferative Diabetic Retinopathy (NPDR)- Average Enrolment by Type of Sponsors
- Table 18: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Leading Sponsors

## I would like to order

Product name: 2019 Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

Product link: <https://marketpublishers.com/r/2783F82AB29EN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2783F82AB29EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

